The results were broadly positive but failed to meet the market’s high expectations, reports the Wall Street Journal.
The vaccine, which is being developed together with Merck & Co (known as MSD outside the United States and Canada), reduced the risk of malignant melanoma spreading by 38 percent compared with standard immunotherapy treatment. The risk of recurrence or death was simultaneously reduced by 42 percent.
BREAKING